SagamoreHill Broadcasting

Accuray Receives Shonin Approval for ClearRT™ Helical kVCT Imaging, CE Mark Expected by End of June; Expands Commercial Launch

Retrieved on: 
Thursday, April 22, 2021

The team has more than 18 years\' experience treating patients with the TomoTherapy System and recently upgraded to the Radixact System, the next-generation TomoTherapy platform.

Key Points: 
  • The team has more than 18 years\' experience treating patients with the TomoTherapy System and recently upgraded to the Radixact System, the next-generation TomoTherapy platform.
  • The ClearRT daily targeting images exceeded our expectations, and provided noticeably superior image quality compared to more traditional cone-beam CT available on conventional linear accelerators.
  • The imaging technology will now be available in Japan and the U.S. ClearRT imaging is expected to be accessible to EU customers following receipt of the CE Mark.
  • "\n*ClearRTHelical kVCT Imaging for the RadixactTreatment Delivery System is not available for sale in all markets.

Accuray Receives 510(k) FDA Clearance for ClearRT™ Helical kVCT Imaging for the Radixact® Treatment Delivery System

Retrieved on: 
Tuesday, January 5, 2021

Accuray is planning commercial release of the ClearRT Helical kVCT Imaging for the Radixact System in the Spring of 2021.

Key Points: 
  • Accuray is planning commercial release of the ClearRT Helical kVCT Imaging for the Radixact System in the Spring of 2021.
  • The ClearRT imaging solution is seamlessly integrated into the Radixact System.
  • ClearRT leverages the same simple 5-step delivery workflow that makes the Radixact System easy to use, and easy to adopt.
  • *ClearRTHelical kVCT Imaging for the Radixact Treatment Delivery System is not available for sale in all markets.